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Background: Infertile women might get pregnant sometime after fertility treatment, but today, there is no
prediction model on who will eventually have children. The objective of the present study was to characterize
hormone levels in an arbitrary menstrual cycle in women with unexplained infertility and male infertility, and to
determine the predictive value for long-term possibility of live birth.
Methods: In this cross-sectional study, with 71 infertile women with diagnosis unexplained infertility and male
infertility, blood samples were obtained during the proliferative and secretory phases of an arbitrary menstrual
cycle. Serum concentrations of FSH, LH, AMH, inhibin B, estradiol, progesterone, PRL and TSH were determined. The
predictive value of ovulation and hormonal analysis was determined by identifying the proportion of women with
at least one live birth. Mann Whitney U test, chi2 test and Spearman’s correlation were used for statistical analysis. A
value of p < 0.05 was considered statistically significant.
Results: There were no differences in hormone values and live birth rates between women with unexplained
infertility and male infertility. The best sole predictors of live birth were age of the women, followed by ovulatory
cycle, defined as serum progesterone concentration of greater than or equal to 32 nmol/L, and a serum TSH
concentration of less than or equal to 2.5 mIU/L. Combining the age with the ovulatory cycle and serum TSH less
than or equal to 2.5 mIU/L or serum AMH greater than or equal to 10 pmol/L the predictive value was close to
90%.
Conclusions: Age in combination with the presence of an ovulatory cycle and serum TSH or serum AMH is
predictive for long-term live birth. The advantage of serum AMH compared with serum TSH is the very little
variation throughout the menstrual cycle, which makes it a useful tool in infertility diagnosis.
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The menstrual cycle reflects a complex combination of
synchronized endocrine events in which the hypothal-
amus, the anterior pituitary and the ovaries are involved
[1]. These events are necessary for successful oocyte
development, ovulation, fertilization and implantation.
Gonadotrophin-Releasing Hormone (GnRH), Follicle-
Stimulating Hormone (FSH) and Luteinizing Hormone
(LH) control ovarian function through a sensitive feedback* Correspondence: tiina.murto@kbh.uu.se
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reproduction in any medium, provided the orsystem. A high level of serum FSH in the early follicular
phase, a consequence of reduced ovarian function, is pre-
dictive of impaired pregnancy outcome after infertility
treatment [2] and it has been shown that a combination of
low FSH levels and high LH levels can predict pregnancy
outcome after infertility treatment [3].
Anti-Müllerian hormone (AMH) is a dimeric glycopro-
tein produced by granulosa cells from pre-antral and an-
tral follicles. The main role of AMH is to inhibit follicular
development from primordial to primary follicular stages.
During the menstrual cycle, serum AMH levels are rela-
tively stable [4]. AMH seems also to be a better predictortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hormonal parameters [5,6].
Inhibin B, produced by granulosa cells in antral follicles,
has been suggested as a marker of follicular growth. Low
serum inhibin B levels have been related to elevated levels
of FSH, which have been shown to have an association
with decreased oocyte quality and fertility [4]. The levels
of inhibin B vary more than AMH throughout the men-
strual cycle. However, the combination of concentrations
of AMH and inhibin B is predictive for pregnancy after
infertility treatments [7].
Oestrogen plays important roles in oocyte maturation,
embryo quality and fertilization [8,9]. The most important
oestrogen is estradiol (E) [8], the serum level of which in
combination with that of FSH, and age is predictive of
pregnancy outcome after IVF treatment [10].
Progesterone (P) is the most important hormone for
endometrial development, implantation and maintenance
of pregnancy [11]. Progesterone support during the luteal
phase has been shown to result in significantly better
pregnancy rates as well as live birth rates after infertility
treatment [12,13].
Thyroid hormones influence ovarian function directly
and indirectly through elevated prolactin (PRL) and al-
tered GnRH secretion. In women with thyroid dysfunc-
tions, ovarian insufficiencies are common [14]. Elevated
levels of serum PRL have been associated with menstrual
disorders as a result of its restraining effect on pulsatile
GnRH secretion as well as inhibition of FSH and LH
release [15]. Furthermore, hyperprolactinaemia has been
shown to be associated with ovulatory dysfunction [16]
and both hypothyroidism and hyperprolactinaemia have
been implicated in infertility. However, the association
between pregnancy outcome and serum TSH levels is
controversial. It has been shown that infertile women
with elevated levels of serum TSH have lower pregnancy
rates than women with normal TSH levels [16].
Approximately 10% of all couples worldwide are infertile
[17]. In the western world, women tend to have their first
child at an older age, which decreases overall fertility.
Therefore, we believe that women with tendency of early
ovarian failure will be the most vulnerable group of
women in this respect. The most successful treatment of
infertility is in vitro fertilization (IVF) [18] with pregnancy
rates between 13–43% per single IVF cycle [18-20]. How-
ever, some couples experience repeated failures of preg-
nancy after treatment [21].
Women with unexplained infertility are often consid-
ered to be subfertile, and will eventually become pregnant
spontaneously sometime after fertility treatment [22]. The
possibility of successful pregnancy in the long term de-
pends on the presence of ovulatory menstrual cycles. The
long-term probability of live birth in women with unex-
plained infertility and women with male infertility has toour knowledge not previously been investigated. There-
fore, we studied serum hormone levels in an arbitrary
menstrual cycle and determined the predictive value for
long-term possibility of live birth in women with unex-
plained infertility and male infertility.Methods
Study design and subjects
Seventy-one infertile women, referred to the Fertility Unit
at Karolinska University Hospital Huddinge between 1999
and 2008 participated in the study. Recruitment of the
women was focused on unexplained infertility and male
infertility, as these two groups of patients have normal
menstrual cycles. All women were referred from an out-
patient gynaecological clinic to the Fertility Unit for fur-
ther examination and treatment of infertility. The women
were healthy except for their infertility and did not use
any hormonal medication.
Infertility was determined by way of a standard set of
tests that included hormone analyses and at least two
semen analyses. Tubal passage was demonstrated by
Hysterosalpingo Contrast Sonography (HyCoSy), or, if
needed, laparoscopy was performed to exclude factors
such as endometriosis. Semen analyses were based on
WHO criteria of normality. The final diagnosis was
established after these examinations. The diagnosis of
unexplained infertility was chosen when no explanation
for infertility was found, and the diagnosis of male infer-
tility was set for women whose partner had abnormal
semen analyses.
Most of the women were contacted by telephone five
years after inclusion in the study and asked about preg-
nancy outcome, or the data of live birth was determined
from patient records. Informed consent was obtained from
all participating women and the study was approved by
the Ethics Committee of Karolinska Institutet.Collection of blood samples
Blood samples were obtained at regular intervals during
one arbitrary normal menstrual cycle. In most women
blood was collected three times during the follicular
phase and four times during the luteal phase for assay of
serum FSH, LH, AMH, inhibin B, E, P, PRL and TSH.
All hormones except E and P were analysed in blood
obtained at cycle day 2 to 5. Serum E levels were deter-
mined on three occasions; before the LH surge (LH −6
to LH -1), the early secretory phase (LH 0 to LH +5)
and the mid-luteal phase (LH +6 to LH +9). Progester-
one was assayed in four different samples during the
luteal phase for determination of area under the curve
(AUC), measured as concentration of progesterone/day.
Additionally, the value determined during the mid-luteal
phase (LH +6 to LH +8) is also shown.
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All blood samples were analysed at the same time using
routine methods at the central clinical laboratory (FSH,
LH, E, P and PRL) at Karolinska University Hospital
Huddinge or at the research laboratory, Department of
Obstetrics and Gynaecology, Uppsala University Hospital,
Uppsala, Sweden (TSH, AMH and inhibin B).
Serum concentrations of FSH and LH were measured
using AutoDELFIA hFSH and hLH respectively (Perkin
Elmer, Waltham, Massachusetts, USA). An enzyme-
linked immunosorbent assay (ELISA) (Immunotech, A
Beckman Coulter Company, Marseille, France) was used
to determine serum AMH levels. The intra-assay CV of
the ELISA was 12.3% and the inter-assay CV was 14.2%.
The active Inhibin B Gen II enzyme-linked immuno-
sorbent assay (Diagnostic Systems Laboratories, Inc., A
Beckman Coulter Company, Webster, USA) was used to
measure serum inhibin B levels. The intra-assay CV of the
ELISA was 2.40% and the inter-assay CV was 3.68%. Two
values of inhibin B were determined to be < 7 pg/mL.
These were set to 7.0 pg/mL in the statistical analysis.
Serum E and P were assayed by using Modular Analytics
E170 equipment (Roche, Basel, Switzerland). Levels of
TSH and PRL were measured by using a Roche Cobas
e601 system (Roche, Basel, Switzerland).Definition of ovulation, cut-off values and live birth
Ovulation was established according to Landgren et al.
[23], using a serum P concentration of ≥ 32 nmol/L
(anovulation < 32 nmol/L). For FSH < 7.0 IU/L, for the
FSH:LH ratio ≤ 2.0 [24] and for AMH ≥ 10 pmol/L were
used as cut-off values. The cut-off value for TSH was set
to 2.5 mIU/L according to Baker et al. [25]. Serum con-
centrations of inhibin B and PRL varied considerably;
therefore these hormones were not used for prediction
of live birth. Live birth was defined as delivery of a
healthy child. All live births were considered regardless
of time in relation to the arbitrary cycle and regardless
of whether or not it was spontaneously conceived or







Age years 34 (26–41) 34 (29–39) 0.991
BMI (kg/m2) 22 (18–32) 22 (18–30) 0.670
Age at menarche 13 (10–17) 13 (12–17) 0.627
Menstrual duration
(Days)
5 (4–7) 5 (3–8) 0.746
Menstrual cycle length 28 (24–35) 28 (25–36) 0.781
Data is shown as median and range.Statistical analysis
Statistical analyses were performed using SPSS (Statistical
Package for the Social Sciences) software (SPSS 15.0 for
Windows; SPSS Inc. Chicago, IL). Data is given as median
(range). We used the Mann Whitney U test for compari-
sons between two groups. For comparisons including cat-
egorical variables the χ2 test was applied. Spearman’s
correlation was used for correlation analysis. A value of
p < 0.05 was considered statistically significant.
The predictive value of ovulation and hormonal analysis
was determined by identifying the proportion of women
with at least one live birth 5 years or more after inclusionin the study. The calculation of the predictive value was
performed as previously described [26].
Results
Patient characteristics
Patient characteristics are shown in Table 1. The groups
consisted of 42 women with unexplained infertility and
29 women with male infertility.
Hormone profile and pregnancy outcome in relation to
diagnosis
There were no significant differences in hormone values
or pregnancy outcome in relation to diagnosis when
comparing the women with unexplained infertility and
women with male infertility. Hormone concentrations
and pregnancy outcome in relation to infertility diagno-
sis are shown in Table 2.
Ovulation
Lack of ovulation could be a sign of premature meno-
pause. The occurrence of ovulation did not affect any of
the other hormones or the possibility of a live birth after
5 years or more. The numbers of women that ovulated
in both groups are shown in Table 2.
Correlations
Serum levels of AMH were associated with the FSH:LH
ratio (p < 0.001) (Figure 1), but not with those of FSH,
(p = 0.11). Serum levels of inhibin B were associated
with those of AMH (p = 0.013), but not with those of
FSH, or the FSH:LH ratio (p = 0.266 and 0.112
respectively).
Prediction of pregnancy outcome
None of the studied hormones were good predictors of
long-term pregnancy outcome (Table 3). The best hor-
monal predictor, with a predictive value of 56%, sensi-
tivity of 78% and specificity of 30% was the presence of
ovulatory menstrual cycles (Table 3). However, and not
surprisingly, age was the best predictor of successful
future pregnancies – predictive value 77%, sensitivity
Table 2 Serum hormone levels, ovulation and total live births according to infertility diagnosis
Unexplained infertility Male infertility P-value
LH (IU/L) 4.4 (1.5 - 11.0) n=42 3.8 (1.0 – 13.0) n=29 0.158
FSH (IU/L) 7.2 (3.4 – 23.0) n=42 6.1 (2.5 – 12.0) n=29 0.062
FSH:LH ratio 1.7 (0.5 – 4.2) n=42 1.6 (0.5 – 5.8) n=29 0.949
AMH (pmol/L) 19.3 (1.3 – 60.8) n=42 21.1 (5.3 – 60.8) n=29 0.977
Inhibin B (pg/ml) 37.1 (7.0-95.4) n=41 47.5 (13.0 – 138.4) n=27 0.208
Estradiol LH-6 to LH-1 (pmol/L) 596.0 (186–2330) n=26 675.5 (217–2924) n=22 0.203
Estradiol LH+0 to LH+5 (pmol/L) 661.5 (209–2511) n=40 579.0 (240–3117) n=25 0.535
Estradiol LH+6 to LH+9 (pmol/L) 434.5 (233–2063) n=40 450.5 (235–2053) n=28 0.727
Progesterone, LH+6 to LH+8 (nmol/L) 35 (20 – 66) n=37 42.5 (15–71) n=26 0.121
Progesterone AUC nmol/L/day 204 (33–504) n=37 229 (46 – 410) n=24 0.241
Ovulatory cycle: P ≥32 (nmol/L) 28 of 42 (66.7%) 24 of 29 (82.8%) 0.218
PRL (μg/L) 10.8 (3.8 – 28.0) n=41 11.8 (3.8 – 29.0) n=29 0.971
TSH (mIU/L) 1.3 (0.1 – 3.6) n=41 1.5 (0.4 – 7.7) n=29 0.535
Total live births (%) 20 of 41 (48.8%) 17 of 29 (58.6%) 0.569
Data is shown as median and range and n (%).
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using the three best predictive values: age, presence of
ovulatory cycles as determined by P ≥ 32 nmol/L and
TSH ≤ 2.5 mIU/L increased the probability of predicting
live birth to 88%, with a sensitivity of 100% and specifi-
city of 33%. Since AMH has increased in popularity in
infertility evaluation, we also calculated a combined
predictive value of age, presence of ovulatory cycle and
AMH ≥ 10 pmol/L. This calculation resulted in the pre-
dictive value of 83%, sensitivity of 83% and specificity of
25%. Menstrual cycle length, and serum inhibin B and
PRL concentrations did not predict the later possibility
of a live birth (data not shown).Figure 1 Correlation between serum AMH and the FSH:LH
ratio. Correlation between serum AMH levels and the FSH:LH ratio
in 71 infertile women with diagnosis unexplained infertility and male
infertility. Spearman’s correlation analysis was used. A value of p <
0.05 was considered statistically significant.Discussion
Serum hormone concentrations in 71 women, with diag-
noses unexplained infertility and male infertility, were
studied during one arbitrary natural menstrual cycle to
investigate the possibility of predicting live birth. There
were no significant differences in hormone levels or
pregnancy outcome between women with unexplained
infertility and women with male infertility.
One reason for increased infertility problems in
Sweden is that women tend to delay their pregnancies,
which results in a reduced fertility rate [27]. This is also
seen in the present study where it is shown that women
at the age of 32 or less have the highest chance of a fu-
ture live birth. Age of the women had the best predictive
value of live birth, which is also known from previous
studies [28,29]. The increasing age has also been associ-
ated with a shortening length of the menstrual cycle,
and the women with cycle length < 26 days has been
shown to have significantly lower pregnancy rates after
infertility treatment compared with the women with
cycle length >34 days [30]. However, this could not been
shown in our study, where the menstrual cycle length
was not related to the pregnancy outcome.
The presence of one progesterone value ≥ 32 nmol/L
was indicative of ovulation [23]. In the present study, an
ovulatory cycle as assessed by assay of serum P was a
better predictor of a future live birth than levels of any
of the other hormones. It has previously been suggested
that women with unexplained infertility have diminished
ovarian reserve [31], but this was not noticed in our
study.
The use of AMH for determination of ovarian func-
tion instead of FSH and/or FSH:LH ratio has increased,
and therefore we studied the correlations between
Table 3 Live birth after infertility treatment in 71 infertile women in relation to different predictors
Ovulation a) FSH b) FSH:LH ratio b) AMH b) TSH b) Age b)
Live birth + - + - + - + - + - + -
Test result Normal 29 23 20 18 26 23 30 30 34 28 20 6
Abnormal 8 10 17 15 11 10 7 3 2 5 17 27
Sensitivity% 78.4 54.1 70.3 81.1 94.4 54.1
Specificity% 30.3 45.5 30.3 9.1 15.2 81.8
Predictive value% 55.8 52.6 53.1 50.0 54.8 76.9
a) Ovulation was determined by using progesterone value as an indicator, ≥ 32 nmol/L being considered to represent ovulation (normal).
b) Cut-off values (“Normal”) were determined to be FSH < 7 IU/L, FSH:LH ratio ≤ 2.0, AMH ≥ 10 pmol/L, TSH ≤ 2.5 mIU/L and age ≤ 32 years.
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correlated with the FSH:LH ratio, and also with inhibin
B levels, which leads to the conclusion that AMH
could replace these markers in assessment of ovulatory
function. The advantage of AMH is its capacity to
maintain relative stable levels during the menstrual
cycle [32] although circadian variations have been
observed [33]. The disadvantage of AMH is that there
are still no international standard assays for AMH
measurement, which makes comparison between dif-
ferent laboratories complicated [34].
It has previously been shown that FSH:LH ratio can
be used as predictor of pregnancy outcome in infertile
women [35], but this was not confirmed in the present
study. It has also been demonstrated that AMH is a
better marker than age, FSH on cycle day 3 or inhibin
B for prediction of IVF pregnancy success [36], which
could neither be shown in the present study. However,
our data showed that AMH combined with age and an
ovulatory menstrual cycle was predictive for future live
birth.
There are only limited data on inhibin B and AMH,
and we are not aware of any studies in which groups of
infertile women have been compared. However, there
was considerable individual variation in serum levels of
inhibin B and PRL, which shows that these hormones
are not useful in diagnosis and prediction of live birth
in women with unexplained and male infertility.
We found no differences in TSH levels between
women in the studied groups. Previously, Cramer et al.
[16] demonstrated relatively high TSH levels and rela-
tively low PRL levels in women with male infertility.
Conversely, Arojoki et al. [37] found the lowest TSH
levels in women with male infertility, and the highest
levels of TSH in women with unexplained infertility,
and ovulatory dysfunction. However, menstrual disor-
ders in women with hypothyroidism are more rare
than previously reported [38]. In our study TSH as a
single variable was not predictive for future live birth,
but the combination with age of 32 or less, ovulatory
cycle and TSH ≤ 2.5 mIU/L resulted in a predictive
value of 88%.The strength of the present study is the number of
hormones measured. Eight different hormones were
measured at various occasions during the menstrual
cycle and the patients needed to come to the clinic sev-
eral times during one natural cycle, which may have
been challenging for women undergoing in vitro fertil-
isation. Additionally, our study group was well-defined
in two selected groups; unexplained infertile and male
infertility, while many previous studies have included
patients regardless of cause of infertility. To our know-
ledge, the long-term probability of live birth in women
with unexplained infertility and women with male infer-
tility has not previously been studied.
A weakness of our study is the long recruitment
period, which resulted in a prolonged follow-up time.
Possible factors (e.g. stress) influencing the serum
hormone levels were not taken into account, which
may be considered a drawback.Conclusions
It can be concluded from the present results that there
are no perfect markers for prediction of pregnancy
outcome on a long-term basis; the best is still the age
of the woman. Age in combination with the presence of
an ovulatory cycle and a serum TSH concentration of
≤ 2.5 mIU/L or AMH concentration of ≥ 10 pmol/L is
predictive of live birth in the long term. The advantage
of serum AMH is its only slight variation in concentra-
tion throughout the menstrual cycle, which makes it a
more useful tool in infertility diagnosis than TSH.Competing interests
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